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A B S T R A C T 
Introduction: Patients with diabetes often require 
complex medication regimens. The positive impact 
of pharmacists on improving diabetes management 
or its co-morbidities has been recognised worldwide. 
This study aimed to characterise drug-related 
problems among diabetic patients in Hong Kong 
and their clinical significance, and to explore the 
role of pharmacists in the multidisciplinary diabetes 
management team by evaluating the outcome of 
their clinical interventions.
Methods: An observational study was conducted at 
the Diabetes Clinic of a public hospital in Hong Kong 
from October 2012 to March 2014. Following weekly 
screening, and prior to the doctor’s consultation, 
selected high-risk patients were interviewed by 
a pharmacist for medication reconciliation and 
review. Drug-related problems were identified and 
documented by the pharmacist who presented 
clinical recommendations to doctors to optimise 
a patient’s drug regimen and resolve or prevent 
potential drug-related problems.
Results: A total of 522 patients were analysed and 
417 drug-related problems were identified. The 
incidence of patients with drug-related problems 
was 62.8% with a mean of 0.9 (standard deviation, 
0.6) drug-related problems per patient. The most 
common categories of drug-related problems were 
associated with dosing (43.9%), drug choice (17.3%), 
and non-allergic adverse reactions (15.6%). Drugs 
most frequently involved targeted the endocrine 
or cardiovascular system. The majority (71.9%) of 
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Introduction
Diabetes mellitus is a chronic disease that is 
prevalent worldwide.1 Patients with diabetes often 
require complex medication regimens and are likely 
New knowledge added by this study
• Pharmacists make an important contribution to the identification, resolution, and prevention of drug-related 
problems by medication reconciliation and review. Most problems were related to dosing with moderate 
clinical significance according to Dean and Barber’s validated scale for scoring medication errors. Over half 
of the clinical interventions initiated by pharmacists were accepted or acknowledged by doctors to improve 
medication management.
Implications for clinical practice or policy
• Collaboration between pharmacists and other health care professionals is valuable for the improvement of 
medication safety in the management of diabetes.
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to develop multiple irreversible complications that 
significantly worsen their quality of life.2 Effective 
diabetes management requires collaboration among 
health care professionals in a multidisciplinary 
ORIGINAL ARTICLECME
drug-related problems were of moderate clinical 
significance and 28.1% were considered minor 
problems. Drug-related problems were totally solved 
(50.1%) and partially solved (11.0%) by doctors’ 
acceptance of pharmacist recommendations, or 
received acknowledgement from doctors (5.5%).
Conclusions: Pharmacists, in collaboration with 
the multidisciplinary team, demonstrated a positive 
impact by identifying, resolving, and preventing 
drug-related problems in patients with diabetes. 
Further plans for sustaining pharmacy service in 
the Diabetes Clinic would enable further studies 
to explore the long-term impact of pharmacists in 
improving patients’ clinical outcomes in diabetes 
management.
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通過跨學科方法改善用藥安全及糖尿病治療方案
鍾欣璇、Shweta Anand、黃志基、陳俊明、黃方方、崔俊明、
陳慧賢
引言：糖尿病患者須經常服食多種藥物，而藥劑師被公認為對改善糖
尿病治療方案或其併發症有正面影響。本研究旨在辨識香港糖尿病患
者的藥物相關的問題及其臨床重要性，並透過評估臨床干預的成效，
探討藥劑師在跨學科糖尿病護理團隊中的角色。
方法：我們於2012年10月至2014年3月期間在香港一所公立醫院
的糖尿病診所內進行觀察性研究。研究期間，藥劑師每週為經篩選
後的糖尿病高危患者在醫生診症前進行「藥物整合」（medication 
reconciliation）和「藥物復審」（medication review）。於辨識及記
錄與藥物相關的問題後，向醫生提出臨床建議以優化患者的藥物治療
方案及解決或預防與潛在藥物相關的問題。
結果：被納入研究的522名患者中，與藥物相關的問題共有417項，發
生率為62.8%。平均每名患者有0.9項（標準偏差，0.6項）與藥物相
關的問題。最常見的是與劑量有關的問題（43.9%），其次為藥物的
選擇（17.3%）和非過敏性的不良反應（15.6%），而最常涉及的為
內分泌或心血管科藥物。大多數（71.9%）與藥物相關的問題具有中
度臨床重要性，其餘28.1%被認為屬輕微問題。醫生接受藥劑師建議
後有50.1%的問題得以完全解決，有11.0%的問題得以部分解決，而
5.5%的問題得到醫生確認。
結論：藥劑師與跨學科團隊合作，通過問題識別、解決和預防糖尿病
患者的藥物相關的問題帶出正面影響。在糖尿病診所內繼續維持藥房
服務的計劃，有助將來探討藥劑師對改善控制糖尿病治療方案的長遠
影響。
diabetes management team (DMT). Pharmacists, as 
a part of the DMT, are well positioned to optimise 
pharmacological treatment, educate patients about 
diabetes management, and promote medication 
compliance.3
 The major role of a pharmacist in a DMT is 
to conduct medication reconciliation (MR) and 
medication review—MR is the process of comparing 
a patient’s prescriptions with all their usual 
medications and identifying the most complete and 
updated medication history4; whereas medication 
review aims to review a patient’s medical and drug 
history, assess their current prescriptions, and 
ascertain their drug knowledge and compliance.5 
This enables pharmacists to identify drug-related 
problems (DRPs) that can actually or potentially 
interfere with optimum health outcomes in specific 
patients.6,7 Polypharmacy (concurrent use of 
multiple medications) is commonly seen in people 
with chronic diseases which could lead to potential 
DRPs.8,9 These DRPs might be overlooked by 
prescribers and interfere with diabetes management. 
In several overseas studies, pharmacists have 
implemented timely interventions to resolve or 
prevent DRPs by offering recommendations to 
prescribers, with an acceptance rate of over 60%.10-13
 The positive impact of pharmacists in improv-
ing diabetes management or its co-morbidities has 
also been recognised by interventional and controlled 
observational studies worldwide.14 Greater overall 
improvement in glycosylated haemoglobin, fasting 
plasma glucose, blood pressure, cholesterol levels, 
renal outcomes, and medication adherence has 
been demonstrated in patients who received 
pharmacist-led diabetes services compared with the 
standard care.12,14-30 Few studies, however, have been 
conducted in Hong Kong.17,29 In view of inadequate 
available data and potential for expansion of local 
pharmacy services, more studies are required to 
investigate the future development of a sustainable 
diabetes service provided by pharmacists. 
 This study aimed to characterise DRPs 
among Chinese diabetic out-patients, and to 
define the clinical significance and outcome of 
pharmacist interventions; thereby highlighting 
their contribution to the detection, resolution, and 
prevention of DRPs to improve medication safety 
and diabetes management.
Methods
Study design and setting
An observational study was conducted weekly in 
the Diabetes Clinic at Queen Mary Hospital (QMH) 
from October 2012 to March 2014. The study 
protocol was approved by the Institutional Review 
Board of the University of Hong Kong (HKU)/
Hospital Authority (HA) Hong Kong West Cluster. 
Informed consent was not required for the study. 
Inclusion and exclusion criteria
Patients were included if they were at ‘high risk’ due 
to their multiple disease state and complex drug 
regimen and if they fulfilled the following criteria:
•	 Aged	≥65	years	 (elderly	patients	 are	 considered	
having high risk for DRPs since they usually take 
more drugs than younger patients)
•	 Taking	 five	 or	 more	 medications	 including	 all	
routes of administration, or over-the-counter 
medications (regular or as needed)
•	 Taking	medications	 that	have	a	 low	 therapeutic	
index or require monitoring
•	 Attending	multiple	specialist	clinics
 Nursing home residents were excluded due 
to their relatively low risk for non-compliance, 
compared with community-dwelling elderly patients.
Procedure and materials
The day before the scheduled weekly clinic 
consultation, two researchers screened the medical 
history, previous consultation notes, current 
medications, and latest laboratory results of Chinese 
elderly patients with diabetes to select high-risk 
patients. Selected patient records were printed and 
prepared for quick reference during the medication 
interview. To facilitate data collection, a memo was 
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attached to the patient’s records to indicate patient 
selection. 
 Two pharmacists from QMH and one from the 
HKU attended the clinic on alternate Wednesdays to 
compile a thorough medication history from selected 
patients and conduct an independent medication 
review prior to the medical consultation. During the 
review, pharmacists also recorded medications not 
shown in the Clinical Management System (CMS), 
such as drugs prescribed by general practitioners 
(GPs), over-the-counter products, vitamins, and 
herbal supplements. 
 A MR form (Appendix 1) was then completed 
by pharmacists, documenting the identified DRPs 
and formulating an intervention proposal. The MR 
forms were collected following medical consultation, 
either on the same day or within the next few days. 
Pharmacist intervention
For the selected high-risk patients, pharmacists 
reviewed the patient’s drug regimen and made 
recommendations to doctors for adjustment, 
provided doctors with an updated drug list after MR, 
suggested a need to further investigate a patient’s 
condition, provided drug education to patients 
and caregivers, reinforced the importance of drug 
compliance to patients, and suggested lifestyle 
modifications such as dietary control.
 Drug-related problems were identified 
from the completed MR forms, and pharmacist 
recommendations were collected for analysis. The 
CMS was checked for outcome of intervention. 
Data collection
Demographic data—for example, age, gender, 
drug allergy status, number of regular medications 
obtained from the HA clinics, and the most 
current laboratory results, including glycosylated 
haemoglobin, fasting plasma glucose, and lipids 
(Appendix 2)—were retrieved from the CMS. 
Additional information in terms of medication, 
drug storage methods, smoking status, drinking 
habits, vaccination record, and latest readings from 
self-monitoring of blood glucose (SMBG) was also 
collected.
Data analysis
Demographic data were tabulated as frequency and 
percentage using Microsoft Excel 2010. Primary 
outcomes included the frequency and categories of 
DRPs, drug classes involved, clinical significance of 
DRPs, and outcome of pharmacist interventions. 
The incidence of DRPs was also calculated as the 
percentage of patients with at least one DRP. 
Definition and classification of drug-related 
problems
Using the Pharmaceutical Care Network Europe 
(PCNE) classification system for DRPs V5.01, DRPs 
were categorised as ‘adverse reactions’, ‘drug choice 
problem’, ‘dosing problem’, ‘drug use problem’, 
‘interactions’, or ‘others’.7 This is an established system 
that has been revised several times with tested 
validity and reproducibility11,31 and has been used in 
many studies.9,32,33 When a single drug was associated 
with more than one possible DRP category, the one 
that best described the clinical scenario was chosen. 
Drugs involved in DRPs were categorised according 
to their British National Formulary classification.34 
 The clinical significance of DRPs was 
assessed to determine their actual or potential 
consequence for patient health outcomes. Using a 
validated scale,35 four independent reviewers (two 
pharmacists and two doctors) scored the severity of 
each DRP from 0 (without potential effects on the 
patient) to 10 (lead to a fatal event). A mean score 
of <3 indicated a minor problem (very unlikely to 
cause adverse effects), 3 to 7 indicated a moderate 
problem (likely to cause some adverse effects or 
interfere with therapeutic goals), and >7 indicated 
a severe DRP that could likely cause death or lasting 
impairment. 
 To evaluate prescribers’ acceptance level, 
the outcome of pharmacist interventions was 
categorised as ‘not known’, ‘solved’, ‘partially solved’, 
or ‘not solved’ according to PCNE classification 
V5.01.7 
FIG.  Selection of study patients
7985 Patient 
appointments in 
Diabetes Clinic
652 (8.2%) Selected 
for interview by 
pharmacists
7333 (91.8%) Excluded as they 
aged <65 years, were nursing 
home residents, or took <5 
medications
126 (19.3%) Missed due to 
absence, refusal to take part, or 
time limitations
4 (0.8%) Excluded from 
analysis, because of missing 
key data or they were nursing 
home residents
522 (99.2%) Included 
for analysis
526 (80.7%) 
Interviewed
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Results
Patient demographics and characteristics
During the study period, a total of 652 patients 
were included based on the selection criteria; 526 
(80.7%) were interviewed, of whom 522 (99.2%) were 
analysed (Fig). 
 The mean (± standard deviation) age of the 522 
patients was 75.2 ± 5.4 years (range, 65-91 years). 
The number of prescribed regular HA medications 
ranged from 5 to 17 with a mean of 9 ± 2. The 
demographics and characteristics of patients are 
shown in Table 1.
Categories of drug-related problems
A total of 417 DRPs were identified. Among the 522 
patients analysed, 328 (62.8%) had at least one DRP 
and the mean number of DRPs per patient was 0.9 
± 0.6. The most prevalent DRP category was related 
to dosing (n=183, 43.9%), followed by drug choice 
(n=72, 17.3%) and non-allergic adverse reaction 
(n=65, 15.6%). The subcategories of each of them are 
listed in Table 2.
TABLE 1.  Demographics and characteristics of patients TABLE 1.  (cont'd)
Demographics / characteristics No. (%) of 
patients§
Mean ± SD (range) age (years) 75.2 ± 5.4 (65-91)
Gender
Female 269 (51.5)
Male 253 (48.5)
Drug allergy status
No known 448 (85.8)
Known 74 (14.2)
On medications or supplements other 
than those prescribed by HA clinics
Yes 119 (22.8)
No 403 (77.2)
Care provider in terms of medications
Self 364 (69.7)
Family member 80 (15.3)
Domestic helper 26 (5.0)
Self and family 20 (3.8)
Family and domestic helper 5 (1.0)
Self and domestic helper 3 (0.6)
Community nurses 9 (1.7)
Not recorded 15 (2.9)
Method of storing medications
DAA* 340 (65.1)
Original dispensing bag 125 (23.9)
Others† 22 (4.2)
DAA and original dispensing bag 6 (1.1)
DAA and others 2 (0.4)
Original dispensing bag and others 3 (0.6)
Not recorded 24 (4.6)
Medications brought in with patient
None 428 (82.0)
Some 50 (9.6)
All 14 (2.7)
Not recorded 30 (5.7)
Medication list available on visit
Yes 39 (7.5)
No 431 (82.6)
Not recorded 52 (10.0)
Smoking status
Non-smoker 384 (73.6)
Ex-smoker 100 (19.2)
Current smoker 21 (4.0)
Not recorded 17 (3.3)
Demographics / characteristics No. (%) of 
patients§
Drinking habit
Non-drinker 465 (89.1)
Light drinker 27 (5.2)
Moderate drinker 2 (0.4)
Ex-drinker 5 (1.0)
Not recorded 23 (4.4)
Record of latest SMBG readings available
Yes‡ 267 (51.1)
No or not recorded 255 (48.9)
Received pneumococcal vaccine within 
the past 5 years
Yes 77 (14.8)
No 386 (73.9)
Not recorded or unsure 59 (11.3)
Received influenza vaccine for current year
Yes 164 (31.4)
No 302 (57.9)
Not recorded 56 (10.7)
Received hepatitis B vaccine previously
Yes 8 (1.5)
No 434 (83.1)
Not recorded or unsure 80 (15.3)
Current smoker 21 (4.0)
Not recorded 17 (3.3)
Abbreviations: DAA = dose administration aid; HA = Hospital 
Authority; SD = standard deviation; SMBG = self-monitoring of 
blood glucose
* Examples include pill boxes, monitored dosage systems, and 
patients’ dispensing cabinets
† Examples include film bottles and patients’ plastic bags or 
containers
‡ Patients who did not bring their records but recalled some 
readings were excluded from “yes”
§ Because of rounding, not all percentages total 100
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TABLE 2.  Categories of drug-related problems (DRPs)
Category No. (%) of DRPs (n=417)
Adverse reactions
Side-effects suffered (non-allergic) 65 (15.6)
Drug choice problem 72 (17.3)
Inappropriate drug 8 (1.9)
Inappropriate drug form 2 (0.5)
Inappropriate duplication of therapeutic group or active ingredient 18 (4.3)
Contra-indication for drug 5 (1.2)
No clear indication for drug use 4 (1.0)
No drug prescribed but clear indication 35 (8.4)
Dosing problem 183 (43.9)
Drug dose too low or dosage regimen insufficient 97 (23.3)
Drug dose too high or dosage regimen too frequent 69 (16.5)
Duration of treatment too long 17 (4.1)
Drug use problem
Drug not taken / administered at all 50 (12.0)
Interactions 4 (1.0)
Potential interaction 3 (0.7)
Manifest interaction 1 (0.2)
Others 43 (10.3)
Insufficient awareness of health and diseases (possibly leading to future problems) 33 (7.9)
Inappropriate timing of administration 2 (0.5)
Therapy failure 1 (0.2)
Patient dissatisfied with therapeutic outcome despite taking drugs correctly 7 (1.7)
* In most cases, DRPs were related to poor drug compliance by the patient
TABLE 3.  Classes of medications involved in drug-related problems (DRPs)
Class of medications No. (%) of DRPs 
involved (n=417)
Examples
Cardiovascular system 159 (38.1) Aspirin, perindopril, losartan, valsartan, metoprolol tartrate, 
atenolol, labetalol, simvastatin, atorvastatin, amlodipine, isosorbide 
mononitrate, furosemide, hydrochlorothiazide, hydralazine, warfarin
Endocrine system 190 (45.6)
Insulins 133 (31.9) Regular insulin, isophane insulin, biphasic isophane insulin, insulin 
glargine 
Antidiabetic drugs 56 (13.4) Metformin, gliclazide, sitagliptin
Sex hormones 1 (0.2) Finasteride
Nutrition and blood 21 (5.0) Calcium carbonate, potassium chloride, darbepoetin alfa injection
Gastrointestinal system 14 (3.4) Pantoprazole, rabeprazole, famotidine, digestive enzymes 
Obstetrics, gynaecology and urinary tract disorders 6 (1.4) Prazosin, terazosin, doxazosin
Respiratory system 5 (1.2) Theophylline, ipratropium, salbutamol, beclomethasone, loratadine
Malignant disease and immunosuppression 3 (0.7) Azathioprine, prednisolone
Central nervous system 3 (0.7) Gabapentin, pregabalin, tramadol
Infections 1 (0.2) Isoniazid and rifampicin 
Musculoskeletal and joint diseases 5 (1.2) Allopurinol, colchicine
Skin 1 (0.2) Fluocinolone acetonide cream
Others 1 (0.2) Peritoneal dialysis fluid
Multiple drugs* 8 (1.9) -
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Classes of medications involved in drug-
related problems
The most common classes of medication involved 
were those targeting the endocrine system with 190 
(45.6%) DRPs, followed by cardiovascular system 
with 159 (38.1%) DRPs (Table 3).
Clinical significance of drug-related 
problems
The mean clinical severity scores assigned to DRPs 
ranged from 0.50 to 7.00. The majority of DRPs 
(n=300, 71.9%) were classified as moderate with the 
remainder (n=117, 28.1%) considered minor. No 
clinically severe DRP was identified (Table 4).
Outcome of pharmacist interventions
As Table 5 shows, modifying drug regimens or 
reinforcing compliance by doctors or referral to 
pharmacists solved 209 (50.1%) DRPs. On the other 
hand, 46 (11.0%) DRPs were partially resolved 
by doctors adjusting prescriptions, although not 
according to pharmacist recommendations; 62 
(14.9%) DRPs were not resolved due to patient 
reluctance to change prescriptions, resolution 
considered unnecessary, or for unknown reasons; 
23 (5.5%) DRPs had an unknown outcome because 
these were non-compliance issues not acknowledged 
by doctors. 
Discussion
The incidence of patients with DRPs (62.8%) and the 
mean number of DRPs per patient analysed (0.9) in 
this study were comparable to a Norwegian study 
(59.2% and 1.2, respectively)10 but considerably 
lower than those identified in four overseas studies 
(incidence of 80.7%-90.5%, and mean number 
of DRPs per patient between 1.9 ± 1.2 and 4.6 ± 
1.7).9,11,12,36 Such discrepancies might be attributed to 
variations in patient selection criteria, data collection 
methods, pharmacists’ clinical experience, as well as 
study duration and setting.9,36,37 
 The majority of DRPs were dosing problems 
(43.9%), with “drug dose too low or dosage regimen 
insufficient” as the largest subcategory. In contrast 
to the lower percentage (5.9%-21.6%) in five overseas 
studies,9-12,36 our high prevalence of dosing problems 
was in line with a local study of medication incidents 
among hospital in-patients,38 mostly arising from 
self-adjustment of dosage or frequency, confusion 
about previous dose changes and dosage modification 
by GPs or doctors overseas. These highlight the 
pivotal role of local pharmacists in conducting MR, 
reviewing drug dosages to ensure safety and efficacy, 
monitoring patients’ metabolic control regularly as 
well as reminding patients and/or their caregivers to 
maintain an updated medication list and follow the 
latest drug label instructions.
 Drug choice problem was the second most 
common DRP; 17.3% of DRPs related to this category, 
which is comparable to the findings of two overseas 
studies (9.1%, 23%)9,36 but deviating from others 
(31.8%-30.2%).10,11 The most common subcategory 
was “no drug prescribed but clear indication”, such 
as the omission of angiotensin-converting enzyme 
inhibitor/angiotensin-receptor blocker (ACEI/
ARB) in patients with microalbuminuria or patient’s 
reluctance to use insulin. Hence, pharmacists have 
a role in advising doctors to adhere to the latest 
treatment guidelines and educate patients about the 
treatment benefits of each drug class.39 Other causes 
of problems surrounding drug choice included drug 
duplication and changes to drug choices by GPs to 
prevent side-effects. This suggests that some DRPs 
might have arisen due to the lack of a common 
platform between the public and private health care 
sector for sharing patient information. Pharmacists 
TABLE 4.  Clinical severity scores assigned to drug-related 
problems (DRPs)
Severity Mean score No. (%) of DRPs (n=417)
Minor 0.50 1 (0.2)
1.00 12 (2.9)
1.25 2 (0.5)
1.50 10 (2.4)
1.75 4 (1.0)
2.00 33 (7.9)
2.25 7 (1.7)
2.50 30 (7.2)
2.75 18 (4.3)
Subtotal 117 (28.1)
Moderate 3.00 45 (10.8)
3.25 22 (5.3)
3.50 29 (7.0)
3.75 16 (3.8)
4.00 65 (15.6)
4.25 8 (1.9)
4.50 27 (6.5)
4.75 7 (1.7)
5.00 42 (10.1)
5.25 5 (1.2)
5.50 11 (2.6)
5.75 2 (0.5)
6.00 15 (3.6)
6.50 1 (0.2)
6.75 1 (0.2)
7.00 4 (1.0)
Subtotal 300 (71.9)
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can make a valuable contribution by establishing 
a patient’s drug history by MR and by liaison with 
different health care sectors.
 Adverse reactions were the third most 
common DRP (15.6%). The major types of “side- 
effects suffered (non-allergic)” were insulin-induced 
hypoglycaemia, gastrointestinal disturbances, and 
dizziness caused by antidiabetic drugs, for which 
pharmacists recommended changes in drug choice 
or dosage. Adverse reactions could lead to other 
DRP categories,7 such as drug choice and drug use 
problems. This reflects the pharmacist’s pivotal role 
in reviewing prescribed doses, suggesting dosage 
adjustments to doctors, monitoring adverse effects, 
and providing information about prevention of 
side-effects (such as performing SMBG regularly to 
prevent hypoglycaemia).39 
 Drug use issues were the fourth most common 
category with comparable prevalence (12.0%) with a 
Malaysian study9 although this ranges widely among 
other studies (3.8%-54.2%).10,11,36 Reasons for the 
subcategory of “drug not taken/administered at all” 
included inability to purchase a self-financed item 
due to cost, ignorance of the indications, concern 
about side-effects, and confusion about previous 
regimen changes.40 In our study, pharmacists 
mainly intervened by direct patient counselling, 
recommending reinforcement of patient compliance 
to doctors or suggesting changes to drug regimens. 
Pharmacists could also work closely with other 
DMT members to educate patients about their 
disease and the most updated regimen, address 
drug cost concerns or side-effects, and encourage 
patients to update their medication list and use dose 
administration aids such as pill boxes.41 
 The low prevalence of drug interactions 
(1.0%) was similar to that (0.6%) in a Danish study,36 
although much higher percentages were found 
in three other studies (8.0%-16.3%),9-11 possibly 
ascribed to differences in prescribing practice, 
references used to define drug interactions,9 and 
also because CMS could already detect a range 
of clinically significant interactions when doctors 
issued prescriptions. Nonetheless system checking 
and prompts cannot replace clinical judgement or 
recommendations of alternative regimens. Other 
categories of DRPs included “insufficient awareness 
of health and diseases” (such as poor dietary control) 
TABLE 5.  Outcome of pharmacist interventions
Outcome No. (%) of DRP 
(n=417)
Examples
Problem totally solved 209 (50.1) A patient on perindopril, whose dose was increased in the nephrology clinic at last follow-up, 
presented with hyperkalaemia (serum potassium level, 5.7 mmol/L). Pharmacist suspected the cause 
as the side-effect of ACEI. Physician agreed to cease drug until next follow-up in nephrology clinic
Problem partially solved 46 (11.0) A patient was prescribed with the following antidiabetic drugs by GP: metformin 500 mg BD, sitagliptin 
50 mg OD, and glimepiride 1 mg OD. In view of patient’s renal function (serum creatinine increased 
from 193 µmol/L to 213 µmol/L), pharmacist suggested stopping metformin and changing sitagliptin 
to linagliptin. Physician noted “strongly advised to stop metformin” in CMS, but made no comment on 
changing sitagliptin
Not solved 62 (14.9)
Lack of cooperation of 
patient
5 (1.2) A T2DM patient had good compliance with four oral antidiabetic drugs (metformin 1500 mg BD, 
gliclazide 160 mg BD, sitagliptin 100 mg daily, and acarbose 50 mg TDS). The pharmacist explained 
that the maximum doses of most drugs had already been reached, but the patient still refused 
admission, insulin therapy, or any additional medications. His latest HbA1c was 12.6% and FPG was 
19.6 mmol/L. The doctor recorded the problem in CMS, explained health risks and advised patient to 
attend emergency department if he felt unwell
No need or impossible 
to solve problem
35 (8.4) The pharmacist recorded that a patient would discuss with the doctor in orthopaedics clinic regarding 
calcium carbonate 1000 mg daily due to constipation. The doctor in Diabetes Clinic did not record the 
problem in CMS and kept the current dosage
For unknown reasons 22 (5.3) Furosemide dosage prescribed in cardiology clinic was increased from 20 mg BD to 40 mg mane and 
20 mg nocte by GP due to oedema. The doctor in Diabetes Clinic neither made a record nor changed 
the prescription
Unknown 77 (18.5) A patient took sitagliptin 50 mg instead of 100 mg daily claiming that doctor told her half a tablet 
would be enough. Pharmacist asked the doctor to review but no record was made in CMS and doctor 
continued prescribing 100 mg daily
Others (acknowledged 
by doctor, but no action 
taken)
23 (5.5) A patient who had coronary artery disease, self-adjusted the dosage of metoprolol tartrate from 25 mg 
BD to 25 mg daily. The doctor recorded the problem but did not prescribe the drug (for follow-up in 
cardiology clinic)
Abbreviations: ACEI = angiotensin-converting enzyme inhibitor ; BD = twice daily; CMS = Clinical Management System; DRP = drug-related problems;  
FPG = fasting plasma glucose; GP = general practitioner; HbA1c = glycosylated haemoglobin; mane = every morning; nocte = every night; OD = once daily; 
T2DM = type 2 diabetes mellitus;  TDS = three times daily
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and “inappropriate timing of administration”, but 
this category could also encompass therapy failure 
and inappropriate lifestyle choices, resulting in 
greater variation of prevalence from overseas studies 
(6.8%-46.6%).9-11,36 Pharmacists are ideally positioned 
to advise patients about the importance of diet, 
smoking cessation, regular exercise, and SMBG.22
 The drug classes most implicated in DRPs 
were for the endocrine system (45.6%) followed by 
cardiovascular system (38.1%). These findings were 
not surprising as insulins, oral antidiabetic drugs, 
antihypertensive, antihyperlipidaemic, antiplatelet 
agents, and ACEI/ARB are most commonly 
prescribed to manage diabetes, its co-morbidities 
and complications.11,39 
 The majority of DRPs were classified as 
moderate. Among similar overseas studies, only 
one analysed the clinical significance of DRPs, in 
which 87% had high or medium clinical/practical 
relevance.10 These findings could not be readily 
compared with the present study because of 
different assessment scales, potential variations 
in reviewers’ clinical experience,35 and unknown 
relative proportions of cases with medium and high 
relevance.
 Over half of the DRPs were totally solved as 
doctors implemented pharmacist recommendations. 
The acceptance rate was somewhat similar to that 
observed in two overseas studies (60.2%-62.7%).12,13 
The physicians acknowledged the provision of 
service by pharmacists and were more aware of the 
written recommendations provided by pharmacists. 
In particular, the value of verbal communication 
between different health care professionals in 
resolving or preventing DRPs has been recognised 
in earlier studies,10,42-45 suggesting potential 
improvement in the acceptance rate if pharmacists 
had more time to hand over DRPs by speaking with 
doctors.
 The outcome of pharmacist interventions could 
also be influenced by doctors’ clinical experience and 
familiarity with the new service. Doctors’ acceptance 
level could have been underestimated since some 
of them might have neglected or missed written 
information from pharmacists. This highlights the 
importance of promoting the role of pharmacists to 
doctors and keeping all participating doctors well-
informed.
Difficulties and limitations
This pilot study allowed for an opportunity to assess 
the proportion of patients who might be seen by 
clinical pharmacists in a busy specialist out-patient 
clinic at a teaching hospital. Approximately 10% of 
patients were chosen each week and not all eligible 
patients could be selected owing to time restrictions. 
The number of patients interviewed was further 
limited due to time constraints, patient absence or 
refusal. Local figures from the QMH Diabetes Clinic 
indicate that approximately 7% to 8% of all patients 
who attend the clinic are deemed ‘high risk’, based 
on ongoing work and prioritisation of those taking 
five or more regular medications. Limited work 
space was another consideration. A designated area 
is required to conduct patient interviews. Further 
arrangements could be made with the medical and 
nursing staff in the Diabetes Clinic to access better 
space. 
 This study only described the current situation 
of DRPs. It did not assess the implementation of 
interventions and their impact on patient health 
outcome. As the majority of patients did not bring 
their drugs to the clinic and had no medication 
list available, the MR process was not always 
comprehensive or effective. Only a minority of 
patients could name their regular drugs. The 
majority relied on pharmacist investigation and 
prompts about the colour, shape, package, or 
indication of each drug. Due to the potential 
for misinterpretation, DRP prevalence may be 
underestimated. One possible solution might be 
to show patients samples of commonly prescribed 
medications. Alternatively, selected patients could 
be telephoned in advance and asked to bring along 
their medications, although this measure may not be 
sustainable. A multifaceted promotional campaign 
could be introduced to encourage patients to bring 
their regular medications to clinic. This has been 
shown to be effective in an emergency setting.46
 Although completed MR forms were 
presented to doctors after the interviews, some 
written information might have been missed with 
a consequent lack of response to certain DRPs. 
Pharmacists should ideally have informed doctors 
about every DRP in person, but this was not always 
possible due to time constraints and the great 
volume of patients. In the long run, pharmacists 
should document DRPs and their recommendations 
in the CMS. This would enhance visibility and allow 
doctors to input their response electronically and 
facilitate organised documentation and easy data 
retrieval. 
Future directions
Upon completion of this study, pharmacists have 
been continuing to provide MR and medication 
review services in QMH Diabetes Clinic. They have 
also been collecting data about DRPs to plan for a 
sustainable service. Following a longer study period, 
patient and staff satisfaction surveys could be 
introduced and also control groups added to enable 
comparison of the effectiveness of pharmacist 
intervention. This would further support the 
extension of hours of service and potentially the 
setup of similar pharmacy services to other hospitals 
and diabetes clinics in Hong Kong.
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Conclusions 
Approximately two thirds of patients at the Diabetes 
Clinic had at least one DRP. The most frequent 
categories of DRPs were related to dosing, drug 
choice, and non-allergic adverse reaction. Drugs 
targeting the endocrine and cardiovascular systems 
were most commonly involved. The majority of DRPs 
were of moderate clinical significance. Pharmacist 
interventions for over half the DRPs were accepted 
or acknowledged by prescribers. Through effective 
communication and collaboration within the 
multidisciplinary health care team, pharmacists 
had a positive impact on identifying, resolving, 
and preventing DRPs. Future plans to sustain the 
diabetes service will enable more local research to 
enhance medication safety and optimise patients’ 
medication regimens in diabetes management.
Appendices
Additional material related to this article can be 
found on the HKMJ website. Please go to <http://
www.hkmj.org>, and search for the article.
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